(Q36952170)

17 August 2017

Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday (English)

1 reference

17 August 2017

1 reference

2

A O Westfall

1 reference

17 August 2017

J R Curtis

1

1 reference

17 August 2017

H Cheng

series ordinal

3

1 reference

17 August 2017

E Delzell

series ordinal

4

1 reference

17 August 2017

K G Saag

series ordinal

5

1 reference

17 August 2017

language of work or name

English

0 references

publication date

16 May 2008

1 reference

Osteoporosis International

17 August 2017

1 reference

17 August 2017

19

1 reference

17 August 2017

11

1 reference

17 August 2017

1613-1620

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-008-0604-4

17 August 2017

0 references

cites work

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574626

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574626

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574626

Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574626

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574626

Severely suppressed bone turnover: a potential complication of alendronate therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574626

Identification of fractures from computerized medicare files

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574626

Ten years' experience with alendronate for osteoporosis in postmenopausal women

27 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-008-0604-4

Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-008-0604-4

Compliance with pharmacologic therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-008-0604-4

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-008-0604-4

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2574626

Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance

4 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18483689

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00198-008-0604-4

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

18483689

1 reference